|
Powered by Cell Signaling Technology |
|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| HQRCLAHsLVGTPNY SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 10945601 |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| Upstream Regulation | |
|---|---|
| Treatments: | |
| Downstream Regulation | |
|---|---|
| Effects of modification on LATS2: | |
| Effects of modification on biological processes: | |
| References | |
|---|---|
|
Zhang C, et al. (2023) Proximal Tubular Ablation Exacerbates Ischemia/Reperfusion Injury (IRI)-Induced Renal Maladaptive Repair through the Upregulation of P53. Int J Mol Sci 24
37894939 Curated Info |
|
|
Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451 Curated Info |
|
|
Guo A (2011) CST Curation Set: 12477; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |
|
|
Guo A (2011) CST Curation Set: 12478; Year: 2011; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info |
|
|
Li Y, et al. (2003) Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene 22, 4398-405
12853976 Curated Info |
Developed with grants from
|
and literature mining with Linguamatics
|
PhosphoSite, created by Cell Signaling Technology is licensed under a Creative
Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
|
©2003-2024 Cell Signaling Technology, Inc.
